Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time.
2024年6月3日，波士顿，(环球新闻社)——Entrada Therapeutics，Inc. (纳斯达克: TRDA)是一家临床阶段的生物制药公司，旨在通过建立一种新的药物类别来影响细胞内长期被认为无法接近的靶标，从而改变患者的生活。该公司今天宣布，首席执行官Dipal Doshi将在高盛第45届全球医疗保健会议上参加一个点火聊天。点火聊天将于2024年6月10日星期一东部时间下午4:00举行。th现场网络直播将在公司网站的投资者关系部分提供。在活动结束后的90天内，Entrada网站上将提供重播。
A live webcast will be available on the Investor Relations section of the Company's website at . A replay will be available on the Entrada website for 90 days following the event.
关于Entrada Therapeutics Entrada Therapeutics是一家临床阶段的生物制药公司，旨在通过建立一种新的药物类别来影响细胞内长期被认为无法接近的靶标，从而改变患者的生活。该公司的内体溶酶体逃逸载体(EEV)-药物是设计用于实现各种活性成分高效的胞内递送到各种器官和组织，从而提高治疗指标。通过这种独有的、多功能的、模块化的方法，Entrada正在推进一个强大的开发组合，包括基于RNA、抗体和酶的项目，潜在地治疗神经肌肉、眼科、代谢和免疫性疾病等。该公司的先导寡核苷酸项目正在开发中，用于治疗患有Duchenne肌萎缩症的人，这些人可进行exon 44、45和50的跳跃适应症。Entrada已与治疗肌萎缩性侧索硬化症1型的临床阶段项目VX-670合作。
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of active moieties into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company's lead oligonucleotide programs are in development for the treatment of people living with Duchenne muscular dystrophy who are exon 44, 45 and 50 skipping amenable. Entrada has partnered VX-670, a clinical-stage program for the treatment of myotonic dystrophy type 1.
有关Entrada Therapeutics的更多信息，请访问我们的网站。请关注我们的LinkedIn。
Entrada Therapeutics是一家临床阶段的生物制药公司，旨在通过建立一种新型药物类别来改善患者的生活，这种药物可以从长期以来被认为无法进入的细胞内靶点入手。该公司的内体逃逸载体（EEV）疗法旨在实现对各种器官和组织中广泛活性物质的高效细胞内输送，从而实现改善治疗指数。通过这种专有的、多功能和模块化的方法，Entrada正在推进一套坚实的发展组合，包括基于RNA、抗体和酶的计划，用于潜在地治疗神经肌肉、眼部、代谢和免疫疾病等多种疾病。该公司的主导寡核苷酸计划正在开发中，用于治疗患有Duchenne肌萎缩症的人，这些人具有外显子44、45和50的跳跃易感性。Entrada已经与VX-670合作，这是一项治疗肌无力症1型的临床阶段计划。
For more information about Entrada, please visit our website, , and follow us on LinkedIn.
投资者和媒体联系 Caileigh Dougherty 投资者关系和企业沟通主管 cdougherty@entradatx.com
Investor and Media Contact
Caileigh Dougherty
Head of Investor Relations and Corporate Communications
cdougherty@entradatx.com
投资者和媒体联系人
投资者和媒体联系
Caileigh Dougherty
投资者关系和企业沟通主管
cdougherty@entradatx.com